Amgen successful in patent litigation against Regeneron and Sanofi relating to Praluent (alirocumab).
Amgen brought an action in the Federal Court of Delaware against Regeneron and Sanofi claiming that the companies violated Amgen patents protecting Repatha (evolocumab) by launch of Praluent (alirocumab) .Both drugs are of the same PCSK 9 inhibitor class. A jury has ruled in favour of Amgen and Amgen has asked for a permanent injunction. Regeneron and Sanofi are to appeal to the Federal Circuit Court of Appeals. A likely outcome may be that Sanofi and Regeneron have to pay royalties to Amgen. However some analysts consider that it is reasonably likely that Praluent will be removed from the US market in 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.